Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn’s disease patientsECCO '18 Vienna
Year: 2018
Authors:

H. Schmitt1*, U. Billmeier1, W. Dieterich1, T. Rath1, S. Sonnewald2, S. Reid2, S. Hirschmann1, K. Hildner1, M.J. Waldner1, J. Mudter3, A. Hartmann4, R. Grützmann5, C. Neufert1, T. Münster6, M.F. Neurath1, R. Atreya1

1Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany, 2Friedrich-Alexander-University Erlangen-Nürnberg, Department of Biology, Erlangen, Germany, 3Sana Kliniken Ostholstein, Eutin, Germany, 4Friedrich-Alexander-University Erlangen-Nürnberg, Deparment of Pathology, Erlangen, Germany, 5Friedrich-Alexander-University Erlangen-Nürnberg, Department of Surgery, Erlangen, Germany, 6Friedrich-Alexander-University Erlangen-Nürnberg, Department of Anesthesiology, Erlangen, Germany

OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Sazonovs1*, N.A. Kennedy2, C. Bewshea2, L. Moutsianas1, G.J. Walker2, K. De Lange1, J. Goodhand2, C. Anderson1, J. Barrett1, PANTS Investigator Consortium, T. Ahmad2

1Wellcome Trust Sanger Institute, Hinxton, UK, 2University of Exeter, IBD Pharmacogenetics, Exeter, UK

OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for inflammatory bowel disease and irritable bowel syndromeECCO '18 Vienna
Year: 2018
Authors:

A. Vich Vila1*, F. Imhann1, V. Collij1, S.A. Jankipersadsing1, T. Gurry2, Z. Mujagic3, A. Kurilshikov1, M.J. Bonder1, J. Xiaofang2, E. Tigchelaar1, J. Dekens1, V. Peters1, M.D. Voskuil1, M.C. Visschedijk1, F. Eleonora A.M.1, G. Dijkstra1, A.A. Masclee3, M.H. Hofker1, R. Xavier4, E.J. Alm2, J. Fu1, C. Wijmenga1, D.M. Jonkers3, A. Zhernakova1, R.K. Weersma1

1University Medical Center Groningen, Groningen, The Netherlands, 2Massachusetts Institute of Technology, Boston, USA, 3Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, 4Broad Institute, Boston, USA

OP015: Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALMECCO '18 Vienna
Year: 2018
Authors:

W. Reinisch1*, R. Panaccione2, P. Bossuyt3, F. Baert4, A. Armuzzi5, S. Travis6, S. Danese7, W.J. Sandborn8, G. D'Haens9, S. Berg10, J.-F. Maa11, J. Petersson11, E. Neimark11, A.M. Robinson11, J.-F. Colombel12

1Medical University of Vienna, Vienna, Austria, 2University of Calgary, Calgary, Canada, 3Imelda General Hospital, Bonheiden, Belgium, 4AZ Delta Roeselare-Menen, Menen, Belgium, 5Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, 6Oxford University Hospitals, Oxford, UK, 7Istituto Clinico Humanitas, Milan, Italy, 8University of California San Diego, La Jolla, USA, 9Academic Medical Center, Amsterdam, The Netherlands, 10AbbVie AB, Solna, Sweden, 11AbbVie Inc., North Chicago, USA, 12Icahn School of Medicine at Mount Sinai, New York, USA

OP016: Need for primary abdominal surgery, but not repeated surgery, has decreased: a nationwide study of temporal trends in Crohn surgery in Sweden 1990–2014ECCO '18 Vienna
Year: 2018
Authors:

D. Kalman1*, C. Nordenvall2, A. Hallqvist Everhov3, J.F. Ludvigsson4, M.C. Sachs5, A. Ekbom6, O. Olén7, P. Myrelid1

1Division of Surgery, Department of Clinical and Experimental Medicine, Faulty of Health Sciences, Linköping University and Department of Surgery, County Council of Östergötland, Linköping, Sweden, 2Department of Molecular Medicine and Surgery, Karolinska Institutet; Center for Digestive Disease, Division of Coloproctology, Karolinska University Hospital, Stockholm, Sweden, 3Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 4Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA, Stockholm, Sweden, 5Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 6Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 7Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Pediatric Gastroenterology and Nutrition, Sachs’ Children and Youth Hospital, Stockholm, Sweden

OP017: Transanal minimally invasive proctectomy with ileal pouch anal anastomosis (Ta-IPAA) in patients with ulcerative colitis: a cohort study from the TaTME international databaseECCO '18 Vienna
Year: 2018
Authors:

G. Pellino1,2*, K. Sahnan2,3, M. Penna3,4, S. Adegbola2,3, P. Chandrasinghe2,3,5, A. Spinelli6,7, R. Hompes4, J. Warusavitarne2,3, on behalf of the International TaTME Registry Collaborative.

1Università della Campania, Unit of Colorectal Surgery, Naples, Italy, 2St Mark's Hospital, Fistula Research Unit, London, UK, 3Imperial College, Department of Surgery and Cancer, London, UK, 4Oxford University Hospital NHS Trust - Churchill Hospital, Department of Colorectal Surgery, Oxford, UK, 5Faculty of Medicine, University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka, 6Humanitas University, Colon and Rectal Surgery Unit, Department of General Surgery, Rozzano, Italy, 7Humanitas University, Humanitas University, Department of Biomedical Sciences, Rozzano, Italy

OP018: High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signallingECCO '18 Vienna
Year: 2018
Authors:

C. Mascaraque1, S. Elangovan2, L. Petti1, A. Piontini2, C. Correale1, V. Arena3, B. Romano1, F. Ungaro2, V. Garlatti2, S. D’Alessio2, G. Fiorino1, A. Spinelli2,4, S. Danese1,2, S. Vetrano2*

1Humanitas Research Institute, IBD Center Laboratory of Immunology in Gastroenterology, Rozzano, Italy, 2Humanitas University, Department of Biomedical Sciences, Rozzano, Italy, 3Catholic University of Rome, Institute of Pathology, Rome, Italy, 4Humanitas Reseach Institute, Colon and Rectal Surgery, Rozzano, Italy

OP019: In faecal microbiota transplantation (FMT) for ulcerative colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short-chain fatty acid production are associated with remission (FOCUS study)ECCO '18 Vienna
Year: 2018
Authors:

S. Paramsothy1,2*, M. Kamm3,4, S. Nielsen1, N. Deshpande1, J. Faith2, J. Clemente2, R. Paramsothy5, A. Walsh6, J. van den Bogaerde7, D. Samuel8, R. Leong8, S. Connor5, W. Ng5, E. Lin9, M. Wilkins1, J.-F. Colombel2, T. Borody9, H. Mitchell1, N. Kaakoush1

1University of New South Wales, Sydney, Australia, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3St Vincent’s Hospital, Melbourne, Australia, 4University of Melbourne, Melbourne, Australia, 5Liverpool Hospital, Sydney, Australia, 6St Vincent’s Hospital, Sydney, Australia, 7Nambour General Hospital, Nambour, Australia, 8Bankstown-Lidcombe Hospital, Sydney, Australia, 9Centre for Digestive Diseases, Sydney, Australia

OP020: The clinical determinants affect gut microbial profile of inflammatory bowel disease patientsECCO '18 Vienna
Year: 2018
Authors:

P. Juillerat1*, B. Yilmaz2, R. Wiest1,2, G. Rogler3, A.J. Macpherson1

1Clinic for Visceral Surgery and Medicine, Gastroenterology, Bern, Switzerland, 2University of Bern, Department of Biomedical Research, Bern, Switzerland, 3University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland

OP021: Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working PartyECCO '18 Vienna
Year: 2018
Authors:

C. Brierley1*, C. Castilla-Llorente2, M. Labopin3, M. Badoglio3, M. Rovira4, E. Ricart5, D. Dierickx6, S. Vermeire7, P. Hasselblatt8, J. Finke9, F. Onida10, A. Cassinotti11, J. Satsangi12, M. Kazmi13, A. López-Sanromán14, D. Farge15, S. Travis16, C. Hawkey17, J. Snowden18

1Oxford University Hospitals, Department of Haematology, Oxford, UK, 2Département d’Hématologie Gustave Roussy, Programme de transplantation des cellules souches, Villejuif, France, 3Université Pierre et Marie Curie, Saint Antoine Hospital, EBMT Paris Study Office, Department of Haematology, Paris, France, 4Hospital Clínic of Barcelona, Haematology Department, Barcelona, Spain, 5Hospital Clínic of Barcelona, Gastroenterology Department, Barcelona, Spain, 6University Hospitals Leuven, Department of Haematology, Leuven, Belgium, 7University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 8Medical Faculty and University Hospital Freiburg, Department of Medicine II, Freiburg, Germany, 9University of Freiburg, Department of Gastroenterology, Freiburg, Germany, 10Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Haematology - BMT Centre, Milan, Spain, 11Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy, 12Western General Hospital, University of Edinburgh, Gastro-intestinal Unit, Institute of Genetics and Molecular Medicine, Edinburgh, UK, 13Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital, Department of Haematology, London, UK, 14Ramon y Cajal Hospital, Gastroenterology and Hepatology Department, Madrid, Spain, 15AP-HP Hôpital Saint-Louis, Centre de Référence des Maladies auto-immunes systémiques Rares d’Ile-de-France (site constitutif), Filière FAI2R, Internal Medicine, Autoimmune and Vascular Diseases Unit, UF 04, Paris, France, 16Oxford University Hospitals, Translational Gastroenterology Unit, Oxford, UK, 17Queen’s Medical Centre, Nottingham Digestive Diseases Centre, School of Clinical Sciences, Nottingham, UK, 18Sheffield Teaching Hospitals NHS Foundation Trust, Department of Haematology, Sheffield, UK

OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST studyECCO '18 Vienna
Year: 2018
Authors:

S. Schreiber1*, L. Peyrin-Biroulet2, B. Boland3, P.D. Higgins4, A. Armuzzi5, J. Terdiman6, W. Zhou7, G. Alperovich8, F. Cataldi7, S. Goteti7, A.P. Lacerda7

1University Hospital Schleswig-Holstein, Kiel, Germany, 2University of Lorraine, Nancy, France, 3University of California, San Diego, San Diego, USA, 4University of Michigan, Ann Arbor, USA, 5Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, 6University of California, San Francisco, Medical Center at Parnassus, San Francisco, USA, 7AbbVie Inc., North Chicago, USA, 8AbbVie Spain S.L.U., Madrid, Spain

OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD)ECCO '18 Vienna
Year: 2018
Authors:

S. Danese1*, B. Feagan2, W. Sandborn3, J.-F. Colombel4, S. Vermeire5, S. Jones6, K. Brennan6, J. Bornstein7

1Humanities University, IBD Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy, 2University of Western Ontario, Robarts Clinical Trials, London, Ontario, Canada, 3University of California, Inflammatory Bowel Disease Center, Division of Gastroenterology, San Diego, USA, 4Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, NY, USA, 5University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 6Europe Development Centre, Takeda R&D, London, UK, 7Takeda Pharmaceuticals International Co., Cambridge, MA, USA

OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II studyECCO '18 Vienna
Year: 2018
Authors:

G.R. D’Haens1*, W. Reinisch2, S.D. Lee3, D. Tarabar4, E. Louis5, M. Kłopocka6, J. Klaus7, S. Schreiber8, D.I. Park9, X. Hébuterne10, F. Cataldi11, A. Banerjee12, K. Gorelick13, W.J. Sandborn14

1Academic Medical Centre, Amsterdam, The Netherlands, 2Medical University of Vienna, Vienna, Austria, 3University of Washington, Seattle, USA, 4Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 5University Hospital CHU of Liège, Liège, Belgium, 6Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 7Universitatsklinikum Ulm, Ulm, Germany, 8University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany, 9Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, 10Université de Nice Sophia Antipolis, Hôpital de l’Archet, Nice, France, 11Shire, Lexington, USA, 12Pfizer, Cambridge, USA, 13Zymo Consulting Group, Newtown Square, USA, 14University of California San Diego, La Jolla, USA

OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysisECCO '18 Vienna
Year: 2018
Authors:

M. Bohm1, S.V. Sagi1, M. Fischer1, S. Kadire1, G. Tran1, M. Rahal1, S. Aniwan2, J. Meserve3, A. Weiss4, G. Kochhar5, P. Shashi5, D. Faleck6, A. Winters6, S. Chablaney6, J.L. Koliani-Pace7, B. Boland3, S. Singh3, R. Hirten6, E. Shmidt6, K. Lasch8, M. Luo8, D. Hudesman9, S. Chang9, D. Lukin4, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, S. Kane2, E.V. Loftus2, B.E. Sands6, W.J. Sandborn3, J.-F. Colombel6, B. Shen5, P.S. Dulai3*

1Indiana University, Indianapolis, USA, 2Mayo Clinic, Rochester, USA, 3University of California - San Diego, La Jolla, USA, 4Montefiore Medical Center, New York, USA, 5Cleveland Clinic Foundation, Cleveland, USA, 6Icahn School of Medicine at Mount Sinai, New York, USA, 7Dartmouth-Hitchcock Medical Center, Lebanon, USA, 8Takeda Pharmaceuticals U.S.A., Inc., Deerfield, USA, 9New York University (NYU), New York, USA, 10North Shore University Hospital, Manhasset, USA, 11Lenox Hill Hospital, New York, USA, 12University of Mississippi, Jackson, USA

OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysisECCO '18 Vienna
Year: 2018
Authors:

D. Faleck1, P. Shashi2, J. Meserve3, M. Rahal4, S. Kadire4, G. Tran4, A. Weiss5, A. Winters1, S. Chablaney1, S. Aniwan6, J.L. Koliani-Pace7, G. Kochhar2, B. Boland3, S. Singh3, R. Hirten1, E. Shmidt1, K. Lasch8, M. Luo8, M. Bohm4, S. V Sagi4, M. Fischer4, D. Hudesman9, S. Chang9, D. Lukin5, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, B. Shen2, W.J. Sandborn3, B.E. Sands1, J.-F. Colombel1, S. Kane6, E.V. Loftus6, P.S. Dulai3*

1Icahn School of Medicine at Mount Sinai, New York, USA, 2Cleveland Clinic Foundation, Cleveland, USA, 3University of California – San Diego, La Jolla, USA, 4Indiana University, Indianapolis, USA, 5Montefiore Medical Center, New York, USA, 6Mayo Clinic, Rochester, USA, 7Dartmouth-Hitchcock Medical Center, Lebanon, USA, 8Takeda Pharmaceuticals U.S.A., Inc., Deerfield, USA, 9New York University (NYU), New York, USA, 10North Shore University Hospital, Manhasset, USA, 11Lenox Hill Hospital, New York, USA, 12University of Mississippi, Jackson, USA

OP027: SUCNR1 receptor mediates intestinal fibrosisECCO '18 Vienna
Year: 2018
Authors:

J. Cosin-Roger1,2*, D. Ortiz-Masia2, D.C. Macias-Ceja1, L. Gisbert-Ferrandiz2, P. Salvador2, M. Hausmann3, G. Rogler3, S. Calatayud2, M.D. Barrachina2

1Fisabio, Hospital Dr Peset, Valencia, Spain, 2University of Valencia, Valencia, Spain, 3University of Zurich, Gastroenterology, Zurich, Switzerland

OP028: Single cell RNA sequencing of t-cells in Crohn’s disease identifies tissue specific drug targetsECCO '18 Vienna
Year: 2018
Authors:

E. Festen1*, R. Weersma1, W.T. Uniken Venema1, M.D. Voskuil1, D. Graham2

1University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, 2The Broad Institute of MIT and Harvard, Cambridge, USA

OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient miceECCO '18 Vienna
Year: 2018
Authors:

M. Yabal1*, A. Wahida1, B. Popper2, K. Steiger3, P. Jost1

1Technical University Munich, III. Medizinische Klinik, Munich, Germany, 2Ludwig-Maximilian University of Munich, Department for Cell Biology, Munich, Germany, 3Technical University Munich, Institut for Pathologie, Munich, Germany

OP030: Loss of PTPN2 in dendritic cells promotes T-cell activation and expression of co-stimulatory moleculesECCO '18 Vienna
Year: 2018
Authors:

L. Hering1*, C. Gottier1, S. Lang1, B. Becher2, G. Rogler1, M. Scharl1, M. Spalinger1

1University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 2University of Zurich, Institute of Experimental Immunologx, Zurich, Switzerland

OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS studyECCO '18 Vienna
Year: 2018
Authors:

N.A. Kennedy1*, G. Heap1,2, B. Hamilton1, G.J. Walker1, C. Bewshea1, S. Bouri3, J. Goodhand1, PANTS Investigator Consortium, T. Ahmad1

1University of Exeter, IBD Pharmacogenetics, Exeter, UK, 2Abbvie, Chicago, USA, 3St Mark’s Hospital, IBD Unit, London, UK